Publication: Comparative study on understanding molecular signatures of ALL and philedelphia positive ALL in adults
No Thumbnail Available
Date
2022-11-16
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Acute lymphoblastic leukemia (ALL) is known to be a very heterogeneous disease together with
identified various genetic abnormalities that causes the disease to be formed. ALL is also known with
its low survival rates. The most commonly seen subtype of ALL is Philadelphia positive ALL (Ph+ALL)
which carries BCR/ABL translocation which is considered as high-risk and the most aggressive subtype.
Ph+ ALL subtype presents drug resistance phenomenon as an obstacle in the treatment process.
Moreover, there has not been novel treatments developed or proposed for the treatment of ALL.
In this study, we aimed to compare the molecular profiles of ALL and Ph+ALL by integrating data from
multiple biomolecular levels. We statistically analyzed 8 ALL and 4 Ph+ALL-associated transcriptomic
datasets using the R/Bioconductor (www.bioconductor.org) software platform. As a result of this
meta-analysis, we found 799 differentially expressed genes (DEGs) for ALL and 295 DEGs for Ph+ALL.
We associated DEGs with reporter molecules receptor, transcription factor, miRNA, metabolites in
addition to reconstruction of protein-protein interaction networks. We also identified hub proteins
according to degree and betweenness centrality. CDKN1A, HSP90AA1, PCNA, PIK3R1, SMARCA4,
YWHAB, and YWHAE in ALL; LYN and RANBP9 in Ph+ALL were prominent as hub proteins. In addition,
we aimed to find a novel and effective therapeutics by using drug repurposing strategy.
The results elucidated by this project will further use in in vitro validation tests and may pave the way
for new clinical trials and clinical applications.
Description
Keywords
Citation
BUDAK B., KİRAZ Y., TURANLI B., \"Comparative Study on Understanding Molecular Signatures of ALL and Philedelphia Positive ALL in Adults\", 4th EURASIA BIOCHEMICAL APPROACHES & TECHNOLOGIES (EBAT) CONGRESS, Antalya, Türkiye, 3 - 06 Kasım 2022